Female sex as a risk factor for thromboembolism and death in patients with incident atrial fibrillation

Summary

Several studies have demonstrated sex differences in risk of thromboembolism and death among patients with atrial fibrillation, but it is unclear to what extent these associations relate to actual physiological differences. To date, no study has investigated sex differences with concomitant control for lifestyle related factors known to influence stroke risk. We used data from the Danish Diet, Cancer and Health study, including 57,053 participants (52% female) aged 50–64 years. The study population for this study included the 2,895 patients (36% female) with incident atrial fibrillation after inclusion. Data were linked to outcomes identified using nationwide registries. Risk of thromboembolism and death according to female sex were analysed using Cox proportional hazards models. After a median follow-up of 5.0 years, 137 men and 62 women suffered a thromboembolic event, and 349 men and 151 women died. In a crude analysis, female sex was associated with a non-significant lower risk of thromboembolism (hazard ratio [HR] 0.82, 95% confidence interval [CI] 0.61–1.11). Adjustment for differences in antithrombotic therapy, relevant comorbidities and lifestyle did not change this association (HR 0.77, 95% CI 0.55–1.13). In the final model, female sex was associated with a lower risk of death (HR 0.65, 95% CI 0.51–0.84). The associations were similar in a sensitivity analysis of women not taking hormone replacement therapy, and the effect of hormone replacement therapy use within females was non-significant for both endpoints of thromboembolism and death. In conclusion, in a relatively young population of patients with atrial fibrillation, female sex was associated with a lower risk of thromboembolism and death.

Keywords

Atrial fibrillation - sex differences - thromboembolism - stroke - death - epidemiology

• References

• 1 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-988.
• 2 Lip GY, Nieuwlaat R, Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010; 137: 263-272.
• 3 Wang TJ, Massaro JM, Levy D. et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. J Am Med Assoc 2003; 290: 1049-1056.
• 4 Camm AJ, Lip GY, De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012; 33: 2719-2747.
• 5 January CT, Wann LS, Alpert JS. et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol. 2014 Epub ahead of print.
• 6 You JJ, Singer DE, Howard PA. et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: e531S-575S.
• 7 Wagstaff AJ, Overvad TF, Lip GY. et al. Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. QJM. 2014 Epub ahead of print.
• 8 Mikkelsen A, Lindhardsen J, Lip GY. et al. Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study. J Thromb Haemost 2012; 10: 1745-1751.
• 9 Tsadok MA, Jackevicius CA, Rahme E. et al. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. J Am Med Assoc 2012; 307: 1952-1958.
• 10 Friberg L, Benson L, Rosenqvist M. et al. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. Br Med J 2012; 344: e3522.
• 11 Cove CL, Albert CM, Andreotti F. et al. Female sex as an independent risk factor for stroke in atrial fibrillation: possible mechanisms. Thromb Haemost 2014; 111: 385-391.
• 12 Zhang Y, Tuomilehto J, Jousilahti P. et al. Lifestyle factors on the risks of ischaemic and hemorrhagic stroke. Arch Intern Med 2011; 171: 1811-1818.
• 13 Tjønneland A, Olsen A, Boll K. et al. Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population-based prospective cohort study of 57, 053 men and women in Denmark. Scand J Public Health 2007; 35: 432-441.
• 14 Thygesen LC, Daasnes C, Thaulow I. et al. Introduction to Danish (nationwide) registers on health and social issues: Structure, access, legislation, and archiving. Scand J Public Health 2011; 39: 12-16.
• 15 Rix TA, Riahi S, Overvad K. et al. Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry. Scand Cardiovasc J 2012; 46: 149-153.
• 16 Overvad K, Tjønneland A, Haraldsdóttir J. et al. Development of a semiquantitative food frequency questionnaire to assess food, energy and nutrient intake in Denmark. Int J Epidemiol 1991; 20: 900-905.
• 17 Tjønneland A, Overvad K, Haraldsdóttir J. et al. Validation of a semiquantitative food frequency questionnaire developed in Denmark. Int J Epidemiol 1991; 20: 906-912.
• 18 Charlson ME, Pompei P, Ales KL. et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
• 19 Thygesen SK, Christiansen CF, Christensen S. et al. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol 2011; 11: 83.
• 20 Abildstrøm SZ, Torp-Pedersen C, Madsen M. Register-based studies of cardiovascular disease. Scand J Public Health 2011; 39: 165-169.
• 21 Albertsen IE, Rasmussen LH, Lane DA. et al. The impact of smoking on thromboembolism and mortality in patients with incident atrial fibrillation: insights from the Danish Diet, Cancer, and Health study. Chest 2014; 145: 559-566.
• 22 Overvad TF, Rasmussen LH, Skjøth F. et al. Alcohol intake and prognosis of atrial fibrillation. Heart 2013; 99: 1093-1099.
• 23 Overvad TF, Rasmussen LH, Skjøth F. et al. Body mass index and adverse events in patients with incident atrial fibrillation. Am J Med 2013; 126: 640.e9-640.e17.
• 24 Pancholy SB, Sharma PS, Pancholy DS. et al. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol 2014; 113: 485-490.
• 25 Hobbs FD, Roalfe AK, Lip GY. et al. Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial. Br Med J 2011; 342: d3653.
• 26 Kimura K, Minematsu K, Yamaguchi T. Atrial fibrillation as a predictive factor for severe stroke and early death in 15, 831 patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry 2005; 76: 679-683.
• 27 Lin HJ, Wolf PA, Kelly-Hayes M. et al. Stroke severity in atrial fibrillation: the Framingham Study. Stroke 1996; 27: 1760-1764.
• 28 Fang MC, Singer DE, Chang Y. et al. Gender differences in the risk of ischaemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study. Circulation 2005; 112: 1687-1691.
• 29 Hart RG, Pearce LA, McBride R. et al. Factors associated with ischaemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. Stroke 1999; 30: 1223-1229.
• 30 Nelson HD, Walker M, Zakher B. et al. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommendations. Ann Intern Med 2012; 157: 104-113.
• 31 Magliano DJ, Rogers SL, Abramson MJ. et al. Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. Br J Obstet Gynecol 2006; 113: 5-14.
• 32 Schierbeck LL, Rejnmark L, Tofteng CL. et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. Br Med J 2012; 345: e6409.
• 33 Johnsen SP, Overvad K, Sørensen HT. et al. Predictive value of stroke and transient ischaemic attack discharge diagnoses in the Danish National Registry of Patients. J Clin Epidemiol 2002; 55: 602-607.
• 34 Helweg-larsen K. The Danish Register of Causes of Death. Scand J Public Health 2011; 39: 26-29.
• 35 Banerjee A, Taillandier S, Olesen JB. et al. Pattern of atrial fibrillation and risk of outcomes: The Loire Valley Atrial Fibrillation Project. Int J Cardiol 2013; 167: 2682-2687.
• 36 De Caterina R, Husted S, Wallentin L. et al. Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Position Paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-1107.
• 37 Sullivan RM, Zhang J, Zamba G. et al. Relation of gender-specific risk of ischaemic stroke in patients with atrial fibrillation to differences in warfarin anticoagulation control (from AFFIRM). Am J Cardiol 2012; 110: 1799-1802.
• 38 Guo Y, Wang H, Zhao X. et al. Relation of renal dysfunction to the increased risk of stroke and death in female patients with atrial fibrillation. Int J Cardiol 2013; 168: 1502-1508.